Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Mossböck, G; Rauscher, T; Winkler, P; Kapp, KS; Langmann, G.
Impact of dose rate on clinical course in uveal melanoma after brachytherapy with ruthenium-106.
Strahlenther Onkol. 2007; 183(10):571-575
Doi: 10.1007/s00066-007-1734-x
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Mossböck Georg
- Co-Autor*innen der Med Uni Graz
- Kapp Karin S.
- Langmann Gerald
- Winkler Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- It has been suggested that the actual dose rate of an irradiating source may be a distinct influencing factor for the biological effect after brachytherapy with ruthenium-106 for uveal melanoma. The purpose of this study was to investigate a hypothesized impact of the dose rate on the clinical and echographic course after brachytherapy. In total, 45 patients were included in this retrospective study. According to the actual dose rate, two groups were defined: group 1 with a dose rate <4 Gy/h and group 2 with a dose rate >or=4 Gy/h. Regarding age, tumor height, basal diameter, scleral and apical dose, differences between the groups were not significant. Clinical parameters, including early and late side effects, and echographic courses were compared. A significantly lower metastatic rate was found in group 2. Using univariate Cox proportional hazards regression, only dose rate predicted metastatic spread significantly (p<0.05), while in a multivariate analysis, using age at the time of treatment, greatest tumor height and greatest basal diameter as covariates, the variable dose rate was of borderline significance (p=0.077). Patients in group 2 had more early side effects and more pronounced visual decline, but these differences were of borderline significance with p-values of 0.072 and 0.064, respectively. These data suggest that a higher dose rate may confer a lower risk for metastatic spread, but may be associated with more side effects and more pronounced visual decline.
- Find related publications in this database (using NLM MeSH Indexing)
- Age Factors -
- Aged -
- Aged, 80 and over -
- Brachytherapy - adverse effects
- Brachytherapy - methods
- Female -
- Follow-Up Studies -
- Humans -
- Male -
- Melanoma - diagnosis
- Melanoma - diagnostic imaging
- Melanoma - radiotherapy
- Middle Aged -
- Multivariate Analysis -
- Neoplasm Metastasis -
- Prognosis -
- Proportional Hazards Models -
- Radiotherapy Dosage -
- Retinal Diseases - etiology
- Retrospective Studies -
- Risk Factors -
- Ruthenium Radioisotopes - administration & dosage
- Ruthenium Radioisotopes - therapeutic use
- Time Factors -
- Ultrasonography -
- Uveal Neoplasms - diagnosis
- Uveal Neoplasms - diagnostic imaging
- Uveal Neoplasms - radiotherapy
- Visual Acuity -
- Find related publications in this database (Keywords)
- uveal melanoma
- Ruthenium-106
- dose rate